Treatment‐related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia
Weili Sun(City Of Hope National Medical Center), Alan S. Wayne(University of Southern California), Susan R. Rheingold(Children's Hospital of Philadelphia), Etan Orgel(Children's Hospital of Los Angeles), Jennifer J. Wilkes(University of Washington), Richard Sposto(Children's Hospital of Los Angeles), Jemily Malvar(University of Southern California), Michael J. Burke(Children's Hospital of Wisconsin), Rebecca Gardner(Seattle Children's Hospital), Alison Smith(University of Southern California), Vanessa P. Tolbert(Seattle Children's Hospital), Minjun Hur, Jill A. Hoffman(University of Southern California)
Cited by 29
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
The treatment of medulloblastoma
|Journal of neurosurgery|1990|583
Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|433